SHARE
 
Barbara A. Blodi, MD close
Barbara A. Blodi, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Barbara A. Blodi, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Barbara A. Blodi earned her medical degree from the University of Iowa in Iowa City and completed her residency at the Bascom Palmer Eye Hospital in Miami.

Specialties

Clinics

UW Health Specialty Clinic - Mauston
(608) 847-7355 | | Map
University Station Clinic
(608) 263-7171 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Ophthalmology and Visual Sciences

Professional Certifications and Education

Board Certification Ophthalmology
Fellowship

Medical Retina, Bascom Palmer Eye Institute, Miami, FL

Surgical Retina, University of Michigan Kellogg Eye Center, Ann Arbor, MI


Residency Bascom Palmer Eye Institute, Miami, FL
Internship Good Samaritan Hospital, Phoenix, AZ
Medical School University of Iowa Carver College of Medicine, Iowa City, IA

Languages Spoken

German
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
Hendrick A VanVeldhuisen PC Scott IU King J Blodi BA Ip MS Khurana RN Oden NL SCORE2 Investigator Group. SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes with Central or Hemiretinal Vein Occlusion Managed with Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials. Am J Ophthalmol . 2020 Aug 20;
[PubMed ID: 32828880]
Regan KA Gottlieb JL Altaweel MM Mititelu M Blodi BA Nork TM Stepien KE Chang JS Alcohol Pads and Nonsterile Gloves in Preparation of Aflibercept. Ophthalmol Retina . 2020 Aug;4(8):853-854
[PubMed ID: 32768034]
Cleland SC Konda SM Danis RP Huang Y Myers DJ Blodi BA Domalpally A Quantification of Geographic Atrophy Using Spectral Domain OCT in Age-Related Macular Degeneration. Ophthalmol Retina . 2020 Jul 15;
[PubMed ID: 32679202]
Spaide RF Jaffe GJ Sarraf D Freund KB Sadda SR Staurenghi G Waheed NK Chakravarthy U Rosenfeld PJ Holz FG Souied EH Cohen SY Querques G Ohno-Matsui K Boyer D Gaudric A Blodi B Baumal CR Li X Coscas GJ Brucker A Singerman L Luthert P Schmitz-Valckenberg S Schmidt-Erfurth U Grossniklaus HE Wilson DJ Guymer R Yannuzzi LA Chew EY Csaky K Monés JM Pauleikhoff D Tadayoni R Fujimoto J Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology . 2020 May;127(5):616-636
[PubMed ID: 31864668]
Etheridge T Dobson ETA Wiedenmann M Papudesu C Scott IU Ip MS Eliceiri KW Blodi BA Domalpally A A semi-automated machine-learning based workflow for ellipsoid zone analysis in eyes with macular edema: SCORE2 pilot study. PLoS One . 2020;15(4):e0232494
[PubMed ID: 32353052]
Guymer RH Rosenfeld PJ Curcio CA Holz FG Staurenghi G Freund KB Schmitz-Valckenberg S Sparrow J Spaide RF Tufail A Chakravarthy U Jaffe GJ Csaky K Sarraf D Monés JM Tadayoni R Grunwald J Bottoni F Liakopoulos S Pauleikhoff D Pagliarini S Chew EY Viola F Fleckenstein M Blodi BA Lim TH Chong V Lutty J Bird AC Sadda SR Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 4. Ophthalmology . 2020 Mar;127(3):394-409
[PubMed ID: 31708275]
Holmen IC Konda SM Pak JW McDaniel KW Blodi B Stepien KE Domalpally A Prevalence and Severity of Artifacts in Optical Coherence Tomographic Angiograms. JAMA Ophthalmol . 2020 Feb 1;138(2):119-126
[PubMed ID: 31804666]
Scott IU Oden NL VanVeldhuisen PC Ip MS Blodi BA Chan CK SCORE2 Investigator Group. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial. JAMA Ophthalmol . 2019 Oct 10;
[PubMed ID: 31600368]
Toh H Smolentsev A Bozadjian RV Keeley PW Lockwood MD Sadjadi R Clegg DO Blodi BA Coffey PJ Reese BE Thomson JA Vascular changes in diabetic retinopathy-a longitudinal study in the Nile rat. Lab Invest . 2019 Oct;99(10):1547-1560
[PubMed ID: 31101854]
Holmen IC Aul B Pak JW Trane RM Blodi B Klein M Clemons T Chew E Domalpally A Age-Related Eye Disease Study 2 Research Group. Precursors and Development of Geographic Atrophy with Autofluorescence Imaging: Age-Related Eye Disease Study 2 Report Number 18. Ophthalmol Retina . 2019 Sep;3(9):724-733
[PubMed ID: 31153849]
Peterson JS Rockwell K Jr Scott IU Ip MS VanVeldhuisen PC Blodi BA SCORE2 Investigator Group. LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS. Retina . 2019 Sep;39(9):1802-1809
[PubMed ID: 29746405]
Scott IU VanVeldhuisen PC Barton F Oden NL Ip MS Blodi BA Worrall M Fish GE Study of Comparative Treatments for Retinal Vein Occlusion 2 Investigator Group. Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol . 2019 Jun 6;
[PubMed ID: 31169862]
Chew EY Clemons TE Jaffe GJ Johnson CA Farsiu S Lad EM Guymer R Rosenfeld P Hubschman JP Constable I Wiley H Singerman LJ Gillies M Comer G Blodi B Eliott D Yan J Bird A Friedlander M Macular Telangiectasia Type 2-Phase 2 CNTF Research Group. Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial. Ophthalmology . 2019 Apr;126(4):540-549
[PubMed ID: 30292541]
Ip MS Oden NL Scott IU VanVeldhuisen PC Blodi BA Ghuman T Baker CW SCORE2 Investigator Group. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study. JAMA Ophthalmol . 2019 Mar 1;137(3):281-287
[PubMed ID: 30589922]
Bradfield Y Barbosa T Blodi B Tompson SW McLellan GJ Struck M Young TL Comparative Intraoperative Anterior Segment OCT Findings in Pediatric Patients with and without Glaucoma. Ophthalmol Glaucoma . 2019 Jul - Aug;2(4):232-239
[PubMed ID: 32672544]
Scott IU VanVeldhuisen PC Ip MS Blodi BA Oden NL Altaweel M Berinstein DM SCORE2 Investigator Group. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. JAMA Ophthalmol . 2018 Apr 1;136(4):337-345
[PubMed ID: 29476687]
Sadda SR Guymer R Holz FG Schmitz-Valckenberg S Curcio CA Bird AC Blodi BA Bottoni F Chakravarthy U Chew EY Csaky K Danis RP Fleckenstein M Freund KB Grunwald J Hoyng CB Jaffe GJ Liakopoulos S Monés JM Pauleikhoff D Rosenfeld PJ Sarraf D Spaide RF Tadayoni R Tufail A Wolf S Staurenghi G Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology . 2018 Apr;125(4):537-548
[PubMed ID: 29103793]
Scott IU Figueroa MJ Oden NL Ip MS Blodi BA VanVeldhuisen PC SCORE2 Investigator Group. SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion. Am J Ophthalmol . 2017 Dec;184:147-156
[PubMed ID: 29074161]
Scott IU VanVeldhuisen PC Ip MS Blodi BA Oden NL King J Antoszyk AN Peters MA Tolentino M SCORE2 Investigator Group. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4. JAMA Ophthalmol . 2017 Jun 1;135(6):639-649
[PubMed ID: 28492860]
Bressler SB Liu D Glassman AR Blodi BA Castellarin AA Jampol LM Kaufman PL Melia M Singh H Wells JA Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol . 2017 Jun 1;135(6):558-568
[PubMed ID: 28448655]